Don’t Use Mounjaro As A Way To Get Skinny: Dr Alexandra Sowa, ‘The Ozempic Revolution’
An obesity and internal medicine specialist based in New York, Dr Alexandra Sowa has been researching and practising obesity medicine for about a decade now. Her new book, titled The Ozempic Revolution, is the first comprehensive user guide to GLP-1s—from the science and pop culture resonances of weight loss drugs and detailed guides to optimising […]
GLP-1 Receptor Agonist Exposure Linked to Neovascular AMD in Patients With Diabetes
FRIDAY, June 6, 2025 — For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk for incident neovascular age-related macular degeneration (nAMD) development, according to a…
Is Novo Nordisk’s Next Generation Obesity Pipeline a Game Changer?
Novo Nordisk NVO has seen strong momentum in recent years, driven by the commercial success of its blockbuster semaglutide products, Wegovy (obesity) and Ozempic (diabetes). Building upon this success, NVO is developing several next-generation candidates in its pipeline, especially targeting the lucrative U.S. market. The most advanced candidate in Novo Nordisk’s pipeline is CagriSema, a […]
EMA considers serious eye condition a ‘very rare’ side effect of semaglutide
The European Medicines Agency said Friday that the product information for Novo Nordisk’s Ozempic and Wegovy should be updated to list a serious eye condition as a “very rare” side effect. A
The ‘golden dose’ of Mounjaro that experts warn could be deadly – as slimmers rave about it saving money
A GROWING number of slimmers are trying to squeeze extra jabs out of empty Mounjaro pens in a risky bid to cut costs. The weight-loss injections, which can cost hundreds of pounds a month, are designed to deliver a fixed amount once a week, typically over four weeks. GettyExperts have warned against trying to get […]
GLP-1 Drug Can Cause Rare, Potentially Blinding Side Effect, EMA Warns
(MedPage Today) — A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, Rybelsus), the European Medicines Agency (EMA) concluded. Following a review of all available data, the…
Women on Weight Loss Drugs Are Having ‘Ozempic Babies’
Ozempic, Wegovy, Mounjaro, and all the other new GLP-1 weight loss drugs are able to miraculously shed pounds. But it seems like they may be canceling out the effects of birth control, too. The UK’s Medicines and Healthcare Products Regulatory Agency, or MHRA, has just issued a warning to women using these medications. They’re letting […]
Design, synthesis, and biological evaluation of long-acting glucagon-like peptide-1 (GLP-1) conjugates modified with dual fatty acids and a proline-alanine-serine (PAS) polypeptide
Publication date: Available online 6 June 2025 Source: Bioorganic & Medicinal Chemistry Author(s): Chengcheng Wang, Jinhua Zhang, Yuanzhen Dong, Jun Xu, Jianguang Lu, Chunyong Ding, Zhengyan Cai, Jun Feng
Ozempic makes you twice as likely to develop this debilitating condition — what that really means for your risk
A new study brings into focus the relationship between diabetic GLP-1 users and the elevated risk of age-related eye disease.
Ozempic has ‘very rare’ sight loss side effect, EU drugs regulator finds
Patients taking weight-loss and diabetes drugs Wegovy and Ozempic have an increased risk of developing a rare eye condition that could lead to loss of vision, a European Medicines Agency (EMA) committee announced Friday. The EMA’s drug safety committee (PRAC) launched a review of medicines containing semaglutide — a GLP-1 agonist and the active ingredient […]